Innogen Pharmaceutical settles in Huangpu

Recently, Guangzhou Innogen Pharmaceutical Group signed an agreement to settle in Huangpu district and Guangzhou High-tech Zone at Guangzhou International Bio-Island.

Established in 2014, Innogen Pharmaceutical focuses on the research and development of innovative drugs in the field of metabolic diseases, particularly achieving significant results in the treatment of diabetes and obesity.

It has become the third global and the first Asian enterprise to possess independent intellectual property rights for human long-acting GLP-1RA. Its innovative drug, Diabegone® (Efsubaglutide Alfa) has been approved for listing, effectively lowering blood sugar levels in type 2 diabetes patients.

Diabegone® (Efsubaglutide Alfa). [Photo/WeChat account: guangzhougaoxinqu]

Upon establishing its presence in Guangzhou, Innogen Pharmaceutical will leverage the ecological advantages of the biomedical industry in the Guangdong-Hong Kong-Macao Greater Bay Area, its international resource connectivity, and policy support systems to further enhance the biomedical industry landscape in Guangzhou High-tech Zone.

As a core area, Guangzhou International Bio-Island has already attracted over 500 biopharmaceutical companies and become an important base for the national bio-pharmaceutical industry.

The addition of Innogen Pharmaceutical will create a synergistic effect with leading enterprises in the area, driving the overall upgrade of the biopharmaceutical industry chain and accelerating the rise of a world-class biopharmaceutical industry cluster.

Share - WeChat